183 related articles for article (PubMed ID: 29338133)
1. Pimasertib-associated ophthalmological adverse events.
van Dijk EHC; Kruit WHJ; Jager MJ; Luyten GPM; Vingerling JR; Boon CJF
Acta Ophthalmol; 2018 Nov; 96(7):712-718. PubMed ID: 29338133
[TBL] [Abstract][Full Text] [Related]
2. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
van Dijk EH; van Herpen CM; Marinkovic M; Haanen JB; Amundson D; Luyten GP; Jager MJ; Kapiteijn EH; Keunen JE; Adamus G; Boon CJ
Ophthalmology; 2015 Sep; 122(9):1907-16. PubMed ID: 26123090
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
[TBL] [Abstract][Full Text] [Related]
4. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
Weber ML; Liang MC; Flaherty KT; Heier JS
JAMA Ophthalmol; 2016 Aug; 134(8):855-62. PubMed ID: 27309887
[TBL] [Abstract][Full Text] [Related]
5. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Niro A; Strippoli S; Alessio G; Sborgia L; Recchimurzo N; Guida M
Am J Ophthalmol; 2015 Nov; 160(5):959-967.e1. PubMed ID: 26231307
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Francis JH; Habib LA; Abramson DH; Yannuzzi LA; Heinemann M; Gounder MM; Grisham RN; Postow MA; Shoushtari AN; Chi P; Segal NH; Yaeger R; Ho AL; Chapman PB; Catalanotti F
Ophthalmology; 2017 Dec; 124(12):1788-1798. PubMed ID: 28709702
[TBL] [Abstract][Full Text] [Related]
7. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
8. PIMASERTIB AND SEROUS RETINAL DETACHMENTS.
AlAli A; Bushehri A; Park JC; Krema H; Lam WC
Retin Cases Brief Rep; 2016; 10(2):191-6. PubMed ID: 26444523
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
Francis JH; Canestraro J; Haggag-Lindgren D; Harding JJ; Diamond EL; Drilon A; Li BT; Iyer G; Schram AM; Abramson DH
Ophthalmol Retina; 2021 Dec; 5(12):1187-1195. PubMed ID: 34102344
[TBL] [Abstract][Full Text] [Related]
11. Transient MEK inhibitor-associated retinopathy in metastatic melanoma.
Urner-Bloch U; Urner M; Stieger P; Galliker N; Winterton N; Zubel A; Moutouh-de Parseval L; Dummer R; Goldinger SM
Ann Oncol; 2014 Jul; 25(7):1437-1441. PubMed ID: 24864047
[TBL] [Abstract][Full Text] [Related]
12. New features in MEK retinopathy.
Tyagi P; Santiago C
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):221. PubMed ID: 30255823
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
Francis JH; Harding JJ; Schram AM; Canestraro J; Haggag-Lindgren D; Heinemann M; Kriplani A; Jhaveri K; Voss MH; Bajorin D; Abou-Alfa GK; Iyer G; Drilon A; Rosenberg J; Abramson DH
JAMA Ophthalmol; 2021 Oct; 139(10):1126-1130. PubMed ID: 34473206
[TBL] [Abstract][Full Text] [Related]
14. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
[TBL] [Abstract][Full Text] [Related]
15. Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2.
Mehta H; Müller S; Egan CA; Degli Esposti S; Tufail A; Sim DA; Holz FG; Browning AC; Amoaku WM; Charbel Issa P; Gillies MC
Br J Ophthalmol; 2017 Jul; 101(7):955-959. PubMed ID: 27793821
[TBL] [Abstract][Full Text] [Related]
16. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
[TBL] [Abstract][Full Text] [Related]
17. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.
Méndez-Martínez S; Calvo P; Ruiz-Moreno O; Pardiñas Barón N; Leciñena Bueno J; Gil Ruiz MDR; Pablo L
Retina; 2019 Aug; 39(8):1435-1450. PubMed ID: 30681641
[TBL] [Abstract][Full Text] [Related]
18. CLINICAL SPECTRUM OF MACULAR-FOVEAL CAPILLARIES EVALUATED WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
Cicinelli MV; Carnevali A; Rabiolo A; Querques L; Zucchiatti I; Scorcia V; Bandello F; Querques G
Retina; 2017 Mar; 37(3):436-443. PubMed ID: 27780174
[TBL] [Abstract][Full Text] [Related]
19. Influence of intravitreal triamcinolone acetonide injection in scleral buckling surgery for macula-off retinal detachment.
Mirshahi A; Karkhaneh R; Zamani Amir J; Movassat M; Azadi P
Ophthalmic Res; 2014; 52(3):160-4. PubMed ID: 25342193
[TBL] [Abstract][Full Text] [Related]
20. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
